Notably, monomeric IgA1 versions of newly and previously characterized bnAbs not only retained IgG neutralization capacity, but also inhibited IgG-mediated enhancement of infection in cells expressing both IgG and IgA Fc receptors. The gene discussed is CD79A; the disease is infection.